Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic obstructive pulmonary disease (COPD)
Biotech
GSK strengthens COPD offering via $12B biobucks Hengrui deal
Having scored approval for Nucala in COPD, GSK has signed a major $12 billion deal to strengthen the pharma’s offering for the respiratory condition.
James Waldron
Jul 28, 2025 4:36am
Roche's COPD drug flunks ph. 3, denting hopes of 2025 approval
Jul 21, 2025 4:38am
Sanofi's IL-33 drug fails COPD study
May 30, 2025 5:30am
Inflammation-focused Upstream to join trickle of biotech IPOs
Sep 19, 2024 4:50am
AstraZeneca IL-33 drug fails to improve COPD breathing in ph. 2
Sep 8, 2024 9:45am
Pneumagen's flu antiviral stands up to human challenge study
Oct 2, 2023 4:00am
